A body-made repair protein. Eye drops eased dry eye discomfort, but the largest trials did not confirm it; a gel eased scalp flaking; skin ulcer benefit came at one strength only. Tendon, muscle, hair and brain claims rest on animals. Weeks of supervised dosing looked safe; long-term self-injection is untested, and tissue studies link it to cancer spread. (Full Review)
| Marker | Target | Why |
|---|---|---|
| High-sensitivity C-reactive protein (hs-CRP) | Below 0.5 mg/L | Tracks the inflammation the peptide is proposed to reduce |
| Complete blood count with differential | Platelets 175–250 ×10⁹/L; white cells 3.5–6.0 ×10⁹/L | Platelets store this peptide; detects injection infection |
| Alanine aminotransferase (ALT) | Below 25 U/L men, 20 U/L women | Baseline organ safety before an unapproved injectable |
| Estimated glomerular filtration rate (eGFR) | Above 90 mL/min/1.73 m² | Kidney enzymes clear this peptide; severe impairment excludes |
| Haemoglobin A1c (HbA1c) | 4.8–5.4% | Poor blood-sugar control impairs the healing targeted |
| Prostate-specific antigen in men, or age-appropriate cancer screening | No target; own baseline is the reference | Addresses the tumour-signalling concern, the only risk with human tissue evidence |
| Antibodies against thymosin beta-4 | No target; no validated clinical assay | Would detect the immune response seen in Phase 1 |
Cadence: Baseline, then metabolic panel and inflammatory marker at 6 weeks and course end, then every 6–12 months if repeated. Cancer screening on the normal age-appropriate schedule.